SG10201913735SA - Lyophilized factor ix formulations - Google Patents

Lyophilized factor ix formulations

Info

Publication number
SG10201913735SA
SG10201913735SA SG10201913735SA SG10201913735SA SG10201913735SA SG 10201913735S A SG10201913735S A SG 10201913735SA SG 10201913735S A SG10201913735S A SG 10201913735SA SG 10201913735S A SG10201913735S A SG 10201913735SA SG 10201913735S A SG10201913735S A SG 10201913735SA
Authority
SG
Singapore
Prior art keywords
formulations
lyophilized factor
lyophilized
factor
Prior art date
Application number
SG10201913735SA
Other languages
English (en)
Inventor
Brian M Thome
Cherie Parkhurst-Lang
Brandon W Leveille
Original Assignee
Bioverativ Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54196282&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201913735S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioverativ Therapeutics Inc filed Critical Bioverativ Therapeutics Inc
Publication of SG10201913735SA publication Critical patent/SG10201913735SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26—DRYING
    • F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B5/00—Drying solid materials or objects by processes not involving the application of heat
    • F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
    • F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mechanical Engineering (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Monitoring And Testing Of Transmission In General (AREA)
  • Mobile Radio Communication Systems (AREA)
SG10201913735SA 2014-03-24 2015-03-24 Lyophilized factor ix formulations SG10201913735SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461969801P 2014-03-24 2014-03-24

Publications (1)

Publication Number Publication Date
SG10201913735SA true SG10201913735SA (en) 2020-03-30

Family

ID=54196282

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201913735SA SG10201913735SA (en) 2014-03-24 2015-03-24 Lyophilized factor ix formulations
SG10201808249VA SG10201808249VA (en) 2014-03-24 2015-03-24 Lyophilized factor ix formulations
SG11201607642RA SG11201607642RA (en) 2014-03-24 2015-03-24 Lyophilized factor ix formulations

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201808249VA SG10201808249VA (en) 2014-03-24 2015-03-24 Lyophilized factor ix formulations
SG11201607642RA SG11201607642RA (en) 2014-03-24 2015-03-24 Lyophilized factor ix formulations

Country Status (16)

Country Link
US (3) US10772942B2 (cg-RX-API-DMAC7.html)
EP (1) EP3123090A4 (cg-RX-API-DMAC7.html)
JP (4) JP7058940B2 (cg-RX-API-DMAC7.html)
KR (1) KR102385372B1 (cg-RX-API-DMAC7.html)
AR (1) AR099838A1 (cg-RX-API-DMAC7.html)
AU (3) AU2015236340B2 (cg-RX-API-DMAC7.html)
CA (1) CA2943034C (cg-RX-API-DMAC7.html)
CL (1) CL2016002386A1 (cg-RX-API-DMAC7.html)
EA (2) EA038573B1 (cg-RX-API-DMAC7.html)
IL (3) IL247869B (cg-RX-API-DMAC7.html)
MA (1) MA39779A (cg-RX-API-DMAC7.html)
MX (2) MX387269B (cg-RX-API-DMAC7.html)
PH (1) PH12016501877A1 (cg-RX-API-DMAC7.html)
SG (3) SG10201913735SA (cg-RX-API-DMAC7.html)
TW (1) TWI700101B (cg-RX-API-DMAC7.html)
WO (1) WO2015148444A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
KR102385372B1 (ko) 2014-03-24 2022-04-11 바이오버라티브 테라퓨틱스 인크. 동결건조된 ix 인자 제형
IL266972B2 (en) * 2016-12-02 2024-04-01 Bioverativ Therapeutics Inc Methods of treating hemophilic arthropathy using chimeric clotting factors
JP7198264B2 (ja) * 2017-07-11 2022-12-28 ユニバーサル スタビリゼイション テクノロジーズ，インコーポレイテッド バイオ医薬品を保存するための方法
CN112175088B (zh) * 2019-07-02 2023-03-28 江苏晟斯生物制药有限公司 改进的fix融合蛋白、缀合物及其应用
CA3168873A1 (en) * 2020-02-04 2021-08-12 Regeneron Pharmaceuticals, Inc. Target residual moisture content for lyophilized drug product
AU2021269585A1 (en) * 2020-05-11 2022-12-15 Mural Oncology, Inc. IL-2 fusion polypeptide compositions and methods of making and using the same
CN118557531B (zh) * 2024-08-02 2024-10-18 成都蓉生药业有限责任公司 一种重组人凝血因子VIII-Fc融合蛋白冻干制剂的制备方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
DE69029799T2 (de) 1989-02-21 1997-05-28 Washington University, St. Louis, Mo. Modifizierte formen von fortpflanzungshormonen
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
SG89295A1 (en) 1991-03-15 2002-06-18 Amgen Inc Pegylation of polypeptides
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
NZ256921A (en) 1992-10-02 1996-05-28 Pharmacia Ab Formulations of coagulation factor viii and a non-ionic surfactant and their preparation
DE4405426A1 (de) 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
IN184589B (cg-RX-API-DMAC7.html) * 1996-10-16 2000-09-09 Alza Corp
US20010031721A1 (en) 1999-05-05 2001-10-18 Chandra Webb Highly concentrated, lyophilized, and liquid factor IX formulations
EP1219298A4 (en) * 1999-09-17 2003-06-11 Takeda Chemical Industries Ltd METHOD FOR PRODUCING PROTEIN POWDER
JP2001151694A (ja) 1999-09-17 2001-06-05 Takeda Chem Ind Ltd タンパク質粉体の製造法
US7091321B2 (en) 2000-02-11 2006-08-15 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of antibody-based fusion proteins
WO2002040544A2 (en) 2000-11-14 2002-05-23 Board Of Regents, University Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
KR20040039328A (ko) 2001-09-04 2004-05-10 메르크 파텐트 게엠베하 변형된 펙터 ⅸ
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
AU2004239244C1 (en) 2003-05-06 2015-04-23 Bioverativ Therapeutics Inc. Clotting factor-Fc chimeric proteins to treat hemophilia
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
JP2005060378A (ja) 2003-07-28 2005-03-10 Yamanouchi Pharmaceut Co Ltd 生理活性蛋白質含有凍結乾燥製剤
US20050152979A1 (en) 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
AU2004298789A1 (en) 2003-12-19 2005-06-30 Novo Nordisk Health Care Ag Stabilised compositions of factor VII polypeptides
JP2007526329A (ja) 2004-03-04 2007-09-13 ワイス 賦形剤の結晶化を改善するための凍結乾燥法
WO2006029467A1 (en) * 2004-09-16 2006-03-23 Btf Pty Ltd Rapid freeze drying process
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
NZ555032A (en) 2004-11-12 2010-02-26 Bayer Healthcare Llc Site-directed modification of FVIII
PT1827483E (pt) 2004-12-15 2014-09-25 Swedish Orphan Biovitrum Ab Publ Formulações terapêuticas do fator de crescimento de queratinócitos
ES2390354T3 (es) * 2005-07-22 2012-11-12 Amgen, Inc Liofilizados de proteínas concentrados, procedimientos y usos
WO2007044616A2 (en) * 2005-10-06 2007-04-19 Xencor, Inc. Optimized anti-cd30 antibodies
EP3593790A1 (en) 2005-11-01 2020-01-15 Wyeth LLC Sodium chloride solution for drug reconstitution or dilution
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
ES2987558T3 (es) 2006-03-24 2024-11-15 Bioverativ Therapeutics Inc PC5 como enzima de procesamiento de propéptido de factor IX
BRPI0709737A2 (pt) 2006-04-04 2011-07-26 Zymenex As processo para concentraÇço de um polipeptÍdeo
EP2423305A1 (en) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
US8015841B2 (en) 2006-09-08 2011-09-13 Praxair Technology, Inc. Cryogenic refrigeration system for lyophilization
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
EA021222B8 (ru) 2007-06-21 2015-11-30 ИксЭль-ПРОТЕИН ГМБХ Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro
EP2209487A4 (en) 2007-10-15 2012-06-20 Univ North Carolina Human factor ix variants with an extended half life
CN101903030A (zh) 2007-12-21 2010-12-01 灵感生物制药学有限公司 含海藻糖的稳定化因子ix制剂
EP2568042A1 (en) 2007-12-27 2013-03-13 Baxter International Inc. Chemically modified factor IX
EP2288622A4 (en) 2008-04-16 2012-04-18 Bayer Healthcare Llc FACTOR IX MODIFIED POLYPEPTIDES AND USES THEREOF
JP2011517950A (ja) 2008-04-16 2011-06-23 バイエル・ヘルスケア・エルエルシー 第ｉｘ因子の部位特異的修飾
EP2811017A2 (en) 2008-04-21 2014-12-10 Novo Nordisk Health Care AG Hyperglycosylated human coagulation factor IX
WO2009130602A2 (en) 2008-04-24 2009-10-29 Celtic Pharma Peg Ltd. Factor ix conjugates with extended half-lives
US9884019B2 (en) 2008-08-05 2018-02-06 Wyeth Llc Lyophilization above collapse
KR20110079670A (ko) 2008-09-24 2011-07-07 스타빌리테크 리미티드 슈가 및 폴리에틸렌이민을 사용하여 폴리펩티드를 보존하는 방법
WO2010148337A1 (en) 2009-06-18 2010-12-23 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
US20120121580A1 (en) * 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
AU2011274414B2 (en) 2010-07-09 2016-10-06 Bioverativ Therapeutics Inc. Factor IX polypeptides and methods of use thereof
WO2012043696A1 (ja) 2010-09-30 2012-04-05 富山化学工業株式会社 ６－フルオロ－３－ヒドロキシ－２－ピラジンカルボキサミドのメグルミン塩
AU2012214419B2 (en) 2011-02-09 2015-12-24 Glaxosmithkline Llc Lyophilized formulations
EP2858659B1 (en) 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Procoagulant compounds
EP3542861A1 (en) * 2012-09-25 2019-09-25 Bioverativ Therapeutics Inc. Methods of using fix polypeptides
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
KR102385372B1 (ko) 2014-03-24 2022-04-11 바이오버라티브 테라퓨틱스 인크. 동결건조된 ix 인자 제형

Also Published As

Publication number Publication date
KR20160137577A (ko) 2016-11-30
CA2943034A1 (en) 2015-10-01
EA038573B1 (ru) 2021-09-16
JP2022044689A (ja) 2022-03-17
AR099838A1 (es) 2016-08-24
EP3123090A4 (en) 2017-12-13
US20210069307A1 (en) 2021-03-11
EP3123090A1 (en) 2017-02-01
JP7759978B2 (ja) 2025-10-24
CA2943034C (en) 2022-06-14
MX2021012939A (es) 2021-11-25
WO2015148444A1 (en) 2015-10-01
AU2020202863A1 (en) 2020-05-21
TW201605492A (zh) 2016-02-16
JP2017510585A (ja) 2017-04-13
IL281197A (en) 2021-04-29
AU2022215218B2 (en) 2025-12-18
IL247869B (en) 2020-02-27
IL247869A0 (en) 2016-11-30
TWI700101B (zh) 2020-08-01
IL281197B (en) 2022-06-01
MA39779A (fr) 2017-02-01
AU2015236340B2 (en) 2020-02-06
CL2016002386A1 (es) 2017-06-23
IL272257B (en) 2021-03-25
US20250121042A1 (en) 2025-04-17
EA201691807A1 (ru) 2017-03-31
PH12016501877A1 (en) 2016-12-19
JP7503583B2 (ja) 2024-06-20
SG10201808249VA (en) 2018-10-30
SG11201607642RA (en) 2016-10-28
KR102385372B1 (ko) 2022-04-11
EA202092926A2 (ru) 2021-07-30
NZ724351A (en) 2023-10-27
MX2016012447A (es) 2017-01-06
IL272257A (en) 2020-02-27
US12128092B2 (en) 2024-10-29
US10772942B2 (en) 2020-09-15
JP7058940B2 (ja) 2022-04-25
AU2020202863B2 (en) 2022-09-01
EA202092926A3 (ru) 2021-10-29
AU2022215218A1 (en) 2022-09-01
JP2020063313A (ja) 2020-04-23
BR112016021777A2 (pt) 2017-10-03
AU2015236340A1 (en) 2016-09-29
MX387269B (es) 2025-03-18
US20170173122A1 (en) 2017-06-22
JP2024053015A (ja) 2024-04-12

Similar Documents

Publication Publication Date Title
TWD174427S (zh) 刮勺
GB201407934D0 (en) Formulation
GB2538413B (en) Blower
IL281197B (en) Formulations of factor ix that have been lyophilized
GB2530868B (en) Blower
GB201419091D0 (en) Formulations
IL276960B (en) Lyophilized formulations for factor xa antidote
GB201419261D0 (en) Formulations
ZA201702401B (en) Composition with reduced immunogenicity
GB201407384D0 (en) Formulation
IL248835A0 (en) A preparation of ciritinib
GB201402448D0 (en) Novel formulation
GB201511301D0 (en) Formulation
IL251362A0 (en) formulation
GB201411371D0 (en) Immunogenic composition
GB201411306D0 (en) Immunogenic composition
GB201416536D0 (en) Formulation
GB201416274D0 (en) Formulation
GB201507784D0 (en) Formulations
GB201505532D0 (en) Formulations
GB201412754D0 (en) Formulation
GB201404773D0 (en) Formulation
GB201502355D0 (en) Composition
GB201410184D0 (en) Odontalgic preparation
TWM490682U (en) Storagable extension-cord socket structure